Plain English Breakdown
The official text states provisions apply retroactively to contracts before January 1, 2026, but does not list a specific effective date for new enforcement.
California Affordable Drug Manufacturing Act of 2020: Opioid Antagonists
This law stops state agencies from giving noncompetitive contracts for opioid antidotes to companies that have settled lawsuits about the opioid crisis.
What This Bill Does
- Prohibits state agencies from awarding noncompetitive contracts under the California Affordable Drug Manufacturing Act of 2020 for opioid antagonists to contractors with multistate settlement agreements regarding their role in the opioid epidemic.
- Makes any contract violating this rule void and unenforceable.
- Applies these rules retroactively to contracts signed before January 1, 2026.
Who It Names or Affects
- State agencies within the California Health and Human Services Agency (CHHSA) or its departments that award noncompetitive drug contracts under this act.
- Contractors who have entered into multistate settlement agreements for their role in contributing to the opioid epidemic.
Terms To Know
- Opioid antagonist
- A drug defined by law that blocks or reverses the effects of opioids, often used to treat overdoses.
- Noncompetitive basis
- Awarding a contract without requiring other companies to bid for it first, such as through negotiation rather than open bidding.
- Multistate settlement agreement
- A legal deal between multiple states and a company that resolves lawsuits about the opioid crisis.
Limits and Unknowns
- The official text does not specify an effective date for when this law begins.
- The source material refers to 'opioid antagonist, as defined' but does not provide the specific definition in the provided excerpts.
- This bill only applies to contracts made under the California Affordable Drug Manufacturing Act of 2020, not all state drug purchases.